Core Insights - BioAtla, Inc. reported its financial results for the full year and fourth quarter ended December 31, 2025, highlighting a focus on advancing its clinical programs while exploring strategic options to maximize shareholder value [1][3]. Corporate Updates - The company initiated a formal process to explore strategic options, including the potential sale of assets and partnerships, engaging Tungsten Advisors as its exclusive financial advisor [3]. - A reduction in force and cost-containment measures were implemented to align resources with near-term priorities, affecting the timing and scope of clinical development programs [4]. - The ongoing Phase 1 study of BA3182 in adenocarcinomas remains a priority, with the company committed to its clinical development despite potential delays [4]. Financial Results - Research and development (R&D) expenses for Q4 2025 were $8.0 million, down from $11.7 million in Q4 2024. For the full year, R&D expenses totaled $43.6 million, compared to $63.1 million in 2024, primarily due to lower program development costs and reduced headcount-related expenses [5]. - Collaboration and other revenue for Q4 2025 was $2.0 million, reflecting a milestone payment from Context Therapeutics, compared to $11.0 million for the full year 2024 [6]. - General and administrative (G&A) expenses decreased to $3.3 million in Q4 2025 from $4.6 million in Q4 2024, with full-year G&A expenses at $17.7 million compared to $21.8 million in 2024 [7]. - The net loss for Q4 2025 was $9.8 million, an improvement from a net loss of $14.9 million in Q4 2024. The full-year net loss was $59.6 million, down from $69.8 million in 2024 [8]. Cash Position - As of December 31, 2025, cash and cash equivalents were $7.1 million, a significant decrease from $49.0 million at the end of 2024 [10][23]. - The company expects to extend its runway through cost reductions and the utilization of a Standby Equity Purchase Agreement while pursuing strategic options [10]. Clinical Pipeline - BioAtla is advancing several clinical assets, including BA3182, a bispecific T-cell engager antibody for advanced adenocarcinoma, and Ozuriftamab Vedotin (Oz-V), targeting oropharyngeal squamous cell carcinoma [13][15]. - Oz-V has received Fast Track Designation from the FDA for treating recurrent or metastatic squamous cell carcinoma of the head and neck, with a potential market opportunity exceeding $7 billion [15]. Patent Portfolio - BioAtla holds extensive patent coverage for its CAB platform technology, with over 780 active patent matters, including more than 500 issued patents, covering various methods and compositions related to its product candidates [11].

Core Insights - BioAtla, Inc. reported its financial results for Q1 2025, highlighting advancements in its Conditionally Active Biologic (CAB) platform and ongoing clinical trials for cancer therapies [1][8]. Financial Performance - Research and development (R&D) expenses for Q1 2025 were $12.4 million, down from $18.9 million in Q1 2024, primarily due to reduced clinical development costs [8]. - General and administrative (G&A) expenses decreased to $5.3 million in Q1 2025 from $5.6 million in Q1 2024 [9]. - The net loss for Q1 2025 was $15.3 million, compared to a net loss of $23.2 million in the same quarter of 2024 [9]. - Cash and cash equivalents as of March 31, 2025, were $32.4 million, down from $49.0 million at the end of 2024, with expectations to fund operations through key clinical readouts in 1H 2026 [11]. Clinical Developments - The Phase 1 dose-escalation study for CAB-EpCAM x CAB-CD3 (BA3182) is ongoing, with the first three patients dosed at 300 micrograms, and data readout expected in mid-2025 [5][6]. - Mecbotamab vedotin (Mec-V) demonstrated a 2-year landmark survival rate of 59% in mKRAS non-small cell lung cancer (NSCLC) patients, significantly higher than the less than 20% survival rate reported for standard care [5][6]. - Ozuriftamab vedotin (Oz-V) continues to show promising results in HPV-positive squamous cell carcinoma of the head and neck, with a disease control rate of 100% and an overall response rate of 45% [6][5]. Strategic Initiatives - The company is utilizing Fast Track Designation from the FDA for discussions regarding a proposed Phase 3 study for Oz-V in treatment-refractory metastatic HPV-positive SCCHN [13]. - BioAtla is focusing on its two internal priority programs and expects cost reductions from its recent restructuring [11]. Upcoming Events - Management will host a conference call and webcast on May 6, 2025, to discuss the financial results and clinical updates [12]. - BioAtla has presentations scheduled at major oncology conferences, including the ASCO Annual Meeting and ESMO Gastrointestinal Cancers Congress [13].

Financial Data and Key Metrics Changes - Research and development (R&D) expenses for Q4 2024 were $11.6 million, down from $22.7 million in Q4 2023, a decrease of $11.1 million due to lower clinical development expenses [30] - General and administrative expenses were $4.6 million for Q4 2024, compared to $5.9 million in Q4 2023, a decrease of $1.3 million primarily due to lower stock-based compensation and personnel-related costs [31] - Net loss for Q4 2024 was $14.9 million, compared to a net loss of $26.9 million in Q4 2023 [31] - Cash and cash equivalents as of December 31, 2024, were $49 million, down from $111.5 million as of December 31, 2023 [32] Business Line Data and Key Metrics Changes - The CAB platform clinical programs are advancing, with promising results from the EpCAM and CAB CD3 bispecific T-cell engager antibody, showing tumor reduction in patients [9][12] - Mecbotamab Vedotin (Mec-V) demonstrated ongoing antitumor activity with multiple confirmed responses among 21 evaluable patients, with a median overall survival not yet reached at 35 months [15] - Ozuriftamab Vedotin (Oz-V) is showing a compelling clinical profile in treatment-refractory head and neck cancer patients, with a 100% disease control rate in HPV-positive patients [20][21] Market Data and Key Metrics Changes - The company is targeting a worldwide commercial opportunity of over $1 billion in peak sales for the second-line plus head and neck cancer population [22] - The overall survival rates for patients with MKRAS non-small cell lung cancer treated with Mec-V were reported at 66% and 58% at one and two years, respectively, exceeding standard care outcomes [15] Company Strategy and Development Direction - The company is focusing on advancing its internal priority programs while streamlining resources, including a workforce reduction of over 30% [28] - Discussions with potential collaborators for Phase 2 assets are ongoing, with a focus on the promising results from the CAB program [33] - The company is open to partnering discussions for various programs, including ROR2 and CTLA-4, to maximize shareholder value [78] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about the clinical outcomes from the CAB program, highlighting its potential to transform treatment options for patients [33] - The company anticipates that the compelling results from its clinical trials will serve as important catalysts for future growth and partnerships [34] Other Important Information - The company has received fast track designation and actionable guidance from the FDA for the Oz-V monotherapy trial design [18] - The safety profile of Evalstotug, a CAB-CTLA-4 antibody, is differentiated with a low incidence of immune-mediated adverse events compared to traditional therapies [25] Q&A Session Summary Question: Update on partnered programs and discussions - Management indicated that discussions are ongoing for the ROR2 and CTLA-4 programs, with new interest expected due to recent data [36][38] Question: Data expectations for BA3182 - The company expects to report on the 300 microgram cohort data in the coming months, with potential for higher doses depending on patient recruitment [44][49] Question: HPV positive patients in head and neck cancer - Management noted that they do not have smoking correlation data for HPV positive patients but will obtain it post-call [63][66] Question: Future patient data for AXL program - The company plans to add more patients to the AXL program and is currently prioritizing the EpCAM program due to its broad applicability [75][76] Question: Strategic partnerships beyond ROR2 and CTLA-4 - Management is open to partnerships for other promising programs and is actively exploring various strategies to maximize shareholder value [78]